Literature DB >> 15517888

Immunocytochemical and pharmacological characterisation of P2-purinoceptor-mediated cell growth and death in PC-3 hormone refractory prostate cancer cells.

Robert C Calvert1, Majid Shabbir, Cecil S Thompson, Dimitri P Mikhailidis, Robert J Morgan, Geoffrey Burnstock.   

Abstract

BACKGROUND: Extracellular nucleotides (e.g adenosine 5'-triphosphate, ATP) influence biological processes via purinergic receptors. We characterised the P2-purinoreceptors in human hormone refractory prostate cancer (HRPC) cells (PC-3 cells).
RESULTS: 1. Immunofluorescent staining demonstrated P2X3 P2X, P2X5 P2X7 and P2Y2 receptors. 2. ATP inhibited cell growth by up to 91% over 72h. Pharmacological characterisation indicated a P2X-purinoreceptor-mediated response. 3. Comparable maximum growth inhibition was seen after either a single addition of 1mM or daily addition of 100mM ATP. ATP concentrations ([ATP]) returned to baseline levels within 24h if the initial [ATP] was < or =100 HM, while [ATP] remained high for 72h if a single concentration of 1 mM was used. 4. ATP 1 mM significantly (p<0.001) increased the proportion of cells undergoing apoptosis from 0.27% (+/- 0.04%) to 5.28% (+/- 0.77%).
CONCLUSION: Threshold concentrations of ATP inhibited HRPC cell growth in vitro via the activation of P2X-purinoreceptors. The role of nucleotides in the treatment of HRPC requires further investigation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15517888

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  14 in total

Review 1.  Molecular and functional properties of P2X receptors--recent progress and persisting challenges.

Authors:  Karina Kaczmarek-Hájek; Eva Lörinczi; Ralf Hausmann; Annette Nicke
Journal:  Purinergic Signal       Date:  2012-05-01       Impact factor: 3.765

Review 2.  Pharmacology of P2X channels.

Authors:  Joel R Gever; Debra A Cockayne; Michael P Dillon; Geoffrey Burnstock; Anthony P D W Ford
Journal:  Pflugers Arch       Date:  2006-04-29       Impact factor: 3.657

Review 3.  Activation and regulation of purinergic P2X receptor channels.

Authors:  Claudio Coddou; Zonghe Yan; Tomas Obsil; J Pablo Huidobro-Toro; Stanko S Stojilkovic
Journal:  Pharmacol Rev       Date:  2011-07-07       Impact factor: 25.468

4.  P2Y2 purinergic receptor modulates virus yield, calcium homeostasis, and cell motility in human cytomegalovirus-infected cells.

Authors:  Saisai Chen; Thomas Shenk; Maciej T Nogalski
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-03       Impact factor: 11.205

5.  Potential role of P2X7R in esophageal squamous cell carcinoma proliferation.

Authors:  André A Santos; Angélica R Cappellari; Fernanda O de Marchi; Marina P Gehring; Aline Zaparte; Caroline A Brandão; Tiago Giuliani Lopes; Vinicius D da Silva; Luis Felipe Ribeiro Pinto; Luiz Eduardo Baggio Savio; Aline Cristina Abreu Moreira-Souza; Robson Coutinho-Silva; Juliano D Paccez; Luiz F Zerbini; Fernanda B Morrone
Journal:  Purinergic Signal       Date:  2017-04-11       Impact factor: 3.765

Review 6.  The P2 purinoceptors in prostate cancer.

Authors:  Zilin Wang; Sha Zhu; Sirui Tan; Yuhao Zeng; Hao Zeng
Journal:  Purinergic Signal       Date:  2022-06-30       Impact factor: 3.765

7.  In silico analysis of the transportome in human pancreatic ductal adenocarcinoma.

Authors:  A Zaccagnino; C Pilarsky; D Tawfik; S Sebens; A Trauzold; I Novak; A Schwab; H Kalthoff
Journal:  Eur Biophys J       Date:  2016-09-21       Impact factor: 1.733

Review 8.  Extracellular ATP and cancer: an overview with special reference to P2 purinergic receptors.

Authors:  Tamás Deli; László Csernoch
Journal:  Pathol Oncol Res       Date:  2008-06-25       Impact factor: 3.201

Review 9.  Autocrine and paracrine purinergic signaling in the most lethal types of cancer.

Authors:  M Reyna-Jeldes; M Díaz-Muñoz; J A Madariaga; C Coddou; F G Vázquez-Cuevas
Journal:  Purinergic Signal       Date:  2021-05-12       Impact factor: 3.765

Review 10.  P2Y receptors for extracellular nucleotides: Contributions to cancer progression and therapeutic implications.

Authors:  Lucas T Woods; Kevin Muñoz Forti; Vinit C Shanbhag; Jean M Camden; Gary A Weisman
Journal:  Biochem Pharmacol       Date:  2021-01-04       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.